ACADIA Pharma Announces Exclusive License Agreement With Neuren Pharma For North American Development and Commercialization Of Trofinetide in Rett Syndrome; Co. Will Pay Neuren $10M Upfront Plus $455M In Potential Milestone and Royalty Payments